v3.26.1
Statement of Financial Position - Veraxa Biotech Holding A G [Member]
Dec. 31, 2025
CHF (SFr)
ASSETS  
Cash SFr 101,000
Total Assets 101,000
LIABILITIES AND EQUITY  
Accrued expenses 18,000
Due to related party 8,856
Advances-related parties 1,000
Total liabilities 27,856
EQUITY  
Subscribed Capital 100,000
Accumulated deficit (26,856)
Total shareholder’s deficit 73,144
TOTAL LIABILITIES AND EQUITY SFr 101,000